Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
Fiche publication
Date publication
novembre 2022
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Dr LAMBERT Aurélien
Tous les auteurs :
Dupont M, Carlier C, Gower-Rousseau C, Barbier-Lider P, Botsen D, Brasseur M, Burgevin A, Chourbagi C, D'Almeida R, Hautefeuille V, Hentzien M, Lambert A, Lamuraglia M, Lavau-Denes S, Lopez A, Parent D, Slimano F, Brugel M, Bouché O
Lien Pubmed
Résumé
Previous studies have observed an increased incidence of Cetuximab-induced hypersensitivity infusion reactions (CI-IRs) in the southeastern states of the USA. Tick's bites were suspected of generating cross-reactions between cetuximab and alpha-gal. This study aims was to describe the incidence and associated risk factors of CI-IRs, in the French areas chosen according to their Lyme disease incidence.
Mots clés
Alpha-gal, And neck neoplasms, Cetuximab, Head, Hypersensitivity, Infusion reaction, Lyme disease, Risk factors
Référence
BMC Cancer. 2022 11 25;22(1):1219